- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Novel Anti-proliferative Application of Telmisartan and Candesartan: Synergistic Repurposing Strategy Against Colorectal Cancer | ||
| Al- Anbar Medical Journal | ||
| Volume 21, Issue 4, October 2025, Pages 276-283 PDF (4.54 M) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2025.159472.2232 | ||
| Authors | ||
| Raneen Subhi Atiyah* 1, 2; Rafl M. Kamil3, 4; Trefa M Abdullah1, 5; Ahmed F. Barqee6 | ||
| 1Department of Pharmacy, College of Medicine, Komar University of Science and Technology, Sulaimani, Iraq | ||
| 2Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman, Jordan | ||
| 3Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603, Kuala Lumpur, Malaysia | ||
| 4Department of Pharmacy, Kurdistan Technical Institute, Sulaimani, Iraq | ||
| 5Department of Basic Sciences, College of Pharmacy, University of Sulaimani, Ministry of Health, Kurdistan Region, Iraq | ||
| 6Kurdistan Institution for Strategic Studies and Scientific Research (KISSR), Sulaymaniyah, Iraq | ||
| Abstract | ||
| Background: Colorectal cancer (CRC) remains a significant global health burden with high mortality and rising resistance to chemotherapy. Angiotensin receptor blockers (ARBs), traditionally used to treat hypertension, have recently been shown to have anti-cancer effects by inhibiting the angiotensin II type 1 receptor (AT1). Objectives: To assess the anti-proliferative effects of telmisartan and candesartan on CRC cells and their synergy with chemotherapy. Materials and Methods: This in vitro study used CRC cell lines to assess viability (MTT assay), growth (soft agar), migration (wound healing), cell cycle and apoptosis (flow cytometry), and gene expression of B-cell lymphoma 2 (BCL2), vascular endothelial growth factor (VEGF), and AT1 by quantitative polymerase chain reaction. Results: Telmisartan and candesartan inhibited CRC cell growth in a time- and dose-dependent fashion, with IC₅₀ values ranging from 63 to 274 µM. When combined with doxorubicin or 5-fluorouracil, they reduced chemotherapy IC₅₀ values by up to 11.6-fold, indicating synergistic cytotoxicity (CI < 1). Both ARBs suppressed wound closure by more than 60%, decreased colony formation by over 50%, induced G0/G1 cell cycle arrest (42% to 66%), and markedly increased apoptosis (54.4% with candesartan vs. 4.6% in controls). Additionally, gene expression analysis revealed more than a twofold downregulation of BCL2, VEGF, and AT1. Conclusion: Telmisartan and candesartan show anti-cancer effects in CRC and synergise with chemotherapy, supporting their potential for repurposing. | ||
| Keywords | ||
| Colorectal cancer; Angiotensin receptor blockers; Candesartan; Telmisartan; Anti-proliferative | ||
|
Statistics Article View: 498 PDF Download: 295 |
||